Taurine enhances anticancer activity of cisplatin in human cervical cancer cells

Advances in Experimental Medicine and Biology

Volumn 776, Issue , 2013, Pages 189-198

  Kim, Taehee ^a   Kim, An Keun ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 9; CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; TAURINE; ANTINEOPLASTIC AGENT; CASPASE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; CELL PROLIFERATION; DOSE RESPONSE; ENZYMOLOGY; METABOLISM; PATHOLOGY; UTERINE CERVIX TUMOR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HELA CELLS; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; TAURINE; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

MLCS; MLOWN;

EID: 84878798534     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-6093-0_19     Document Type: Article

References (29)

1. Barbeau A (1975) The brain, the heart and taurine. Can J Neurol Sci 2:343-346.
2. Boulikas T, Vougiouka M (2004) Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. Oncol Rep 11:559-595.
3. Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W (2006) Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 12:382-393.
4. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X (1999) Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15:269-290.
5. Chen XC, Pan ZL, Liu DS, Han X (1998) Effect of taurine on human fetal neuron cells: proliferation and differentiation. Adv Exp Med Biol 442:397-403.
6. Chen YX, Zhang XR, Xie WF, Li S (2004) Effects of taurine on proliferation and apoptosis of hepatic stellate cells in vitro. Hepatobiliary Pancreat Dis Int 3:106-109.
7. Chène P (2001) Targeting p53 in cancer. Curr Med Chem Anticancer Agents 1:151-161.
8. Danielsson H, Sjövall J (1975) Bile acid metabolism. Annu Rev Biochem 44:233-253.
9. Fan TJ, Han KH, Cong RS, Kiang J (2005) Caspase-family proteases and apoptosis. Acta Biochim Biophys Sin 37:719-727.
10. Ghavami G, Kazemali MR, Sardari S (2011) Informatics of drug synergism in naturally occurring anticancer agents. Recent Pat Anticancer Drug Discov 6:26-44.
11. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409-422.
12. Gottlieb JA, Drewinko B (1975) Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 59:621-628.
13. Hamaguchi T, Azuma J, Awata N, Ohta H, Takihara K, Harada H, Kishimoto S, Sperelakis N (1988) Reduction of doxorubicin-induced cardiotoxicity in mice by taurine. Res Commun Chem Pathol Pharmacol 59:21-30.
14. Hamaguchi T, Azuma J, Harada H, Takahashi K, Kishimoto S, Schaffer SW (1989) Protective effect of taurine against doxorubicin-induced cardiotoxicity in perfused chick hearts. Pharmacol Res 21:729-734.
15. Hernández-Benítez R, Ramos-Mandujano G, Pasantes-Morales H (2012) Taurine stimulates proliferation and promotes neurogenesis of mouse adult cultured neural stem/progenitor cells. Stem Cell Res 9(1):24-34.
16. Hong SJ, Dawson TM, Dawson VL (2004) Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci 25:259-264.
17. Huxtable RJ (1992) Physiological actions of taurine. Physiol Rev 72:101-163.
18. Ito T, Muraoka S, Takahashi K, Fujio Y, Schaffer SW, Azuma J (2009) Beneficial effect of taurine treatment against doxorubicin-induced cardiotoxicity in mice. Adv Exp Med Biol 643:65-74.
19. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M (1999) Apoptosis. Molecules and mechanisms. Adv Exp Med Biol 457:217-236.
20. Lima L, Cubillos S (1998) Taurine-stimulated outgrowth from the retina is impaired by protein kinase C activators and phosphatase inhibitors. Adv Exp Med Biol 442:423-430.
21. Maclaine NJ, Hupp TR (2009) The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging 1:490-502.
22. McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13:228-244.
23. Nimmanapalli R, Bhalla K (2003) Targets in apoptosis signaling: promise of selective anticancer therapy. Methods Mol Biol 223:465-483.
24. Porter AG, Jänicke RU (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6:99-104.
25. Saad SY, Al-Rikabi AC (2002) Protection effects of Taurine supplementation against cisplatininduced nephrotoxicity in rats. Chemotherapy 48:42-48.
26. Saif MW, Tytler E, Lansigan F, Brown DM, Husband AJ (2009) Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. Expert Opin Investig Drugs 18:469-479.
27. Sato S, Yamate J, Saito T, Hosokawa T, Saito S, Kurasaki M (2002) Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin. Naunyn Schmiedebergs Arch Pharmacol 365:277-283.
28. Suganuma M, Saha A, Fujiki H (2011) New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci 102:317-323.
29. Yu J, Zhang L (2004) Apoptosis in human cancer cells. Curr Opin Oncol 16:19-24.